Visit the Lenze web site

Consulting services expand

An ARC Advisory Group product story
Edited by the Engineeringtalk editorial team Oct 7, 2002

ARC Advisory Group has expanded its strategic consulting services to include a team dedicated to the pharmaceutical and biotech industries.

ARC Advisory Group has expanded its strategic consulting services to include a team dedicated to the pharmaceutical and biotech industries.

This expansion provides services for the issues facing pharmaceutical-biotech clinical research and manufacturing, commercial manufacturing, and suppliers of automation technology.

The high financial investment coupled with the diversity of new treatments increases risk and drives the need for industry knowledgeable strategic consulting.

With a 12 to 15 year product development cycle costing over $800 million to bring a single drug to market, companies in this industry have many business, supply chain, and manufacturing issues that are unique.

They require specialized knowledge and expertise in regulatory requirements, automation technology, and business best practices.

New drugs and treatments were made possible by tremendous scientific progress in biotechnology, biochemistry, and genetic engineering.

Global awareness creates a high demand for the latest life improving drugs.

These issues plus the demand for cost containment, a wider variety of affordable drugs, and increasing regulatory costs, are redefining the health care industry.

This includes closer relationships with suppliers, closer collaboration from drug development through clinical trials and commercial manufacturing, and the use of leading edge technologies to improve the entire business supply chain and manufacturing processes.

ARC is unique in its ability to provide strategic consulting to pharmaceutical companies so they can better respond to their changing market requirements.

ARC's Pharmaceutical-BioTech Consulting Practice covers logistics, supply chain, automation, control system integration, batch management, regulatory requirements, advanced control, and optimization applications.

Supplier and users alike are focused on the FDA's 21 CFR Part 11 requirements and new drug validation.

Manufacturers in the FDA-regulated industries get a better understanding of currently available technologies and services to help them determine how to meet 21 CFR Part 11 requirements and speed validation.

Not what you're looking for? Search the site.

Back to top Back to top

Google Ads

 

Contact ARC Advisory Group

Related Stories

Contact ARC Advisory Group

 

Newsletter sign up

Request your free weekly copy of the Engineeringtalk email newsletter ...

Visit the Lenze web site

Articles by product category

All suppliers A - Z

A Pro-talk Publication

A Pro-talk publication